Interferon-induced senescent CD8 + T cells reduce anti-PD1 immunotherapy efficacy in early triple-negative breast cancer
Science Translational Medicine · 10.09.2025 · 17 (815)
DOI: 10.1126/scitranslmed.adj7808 ↗Kurz gefasst
Fachartikel in der Zeitschrift Science Translational Medicine, erschienen am 10.09.2025. Verfasst von Tong Fu und 13 weiteren Autor:innen. Beteiligte Einrichtung: Key Laboratory of Breast Cancer in Shanghai, Department of Breast Surgery, Precision Cancer Medicine Center, Fudan University Shanghai Cancer Center,…. Hauptthemen laut MEDLINE: Triple Negative Breast Neoplasms, CD8-Positive T-Lymphocytes, Immunotherapy, Cellular Senescence. Die Arbeit wurde bisher 28-mal zitiert (Crossref) und nennt 69 Literaturangaben.
Abstract (Originalsprache)
Triple-negative breast cancers (TNBCs) lack predictive biomarkers to guide immunotherapy, especially during early-stage disease. To address this issue, we used single-cell RNA sequencing, bulk transcriptomics, and pathology assays on samples from 171 patients with early-stage TNBC receiving chemotherapy with or without immunotherapy. Our investigation identified an enriched subset of interferon (IFN)–induced CD8 + T cells in early TNBC samples, which predict immunotherapy nonresponsiveness. Mechanistically, IFN produced by HLA-DR + monocytes triggered cellular senescence in CD8 + T cells, which was marked by excessive NAD + consumption, reduced cytotoxicity, and immunotherapy nonresponsiveness. Nicotinamide mononucleotide treatment restored the function of IFN-induced senescent CD8 + T cells and enhanced immunotherapy efficacy in patient-derived organoid–T cell coculture and in mouse models. Overall, our study identifies IFN-induced T cell senescence as a driver of immunotherapy nonresponsiveness in early TNBC and provides a strategy to restore CD8 + T cell function for immunotherapeutic benefit.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Key Laboratory of Breast Cancer in Shanghai, Department of Breast Surgery, Precision Cancer Medicine Center, Fudan University Shanghai Cancer Center, Shanghai 200032, P. R. China.
- Department of Immunology, Shanghai Medical School, and Institutes of Biomedical Sciences, Fudan University, Shanghai 200032, P. R. China.
- Shanghai Fifth People's Hospital, Shanghai Key Laboratory of Medical Epigenetics, Institutes of Biomedical Sciences, Fudan University, Shanghai 201100, P. R. China.
- Shanghai Academy of Natural Sciences (SANS), Fudan University, Shanghai 201203, P. R. China.
ORCID-Profile: Tong Fu, Xi Jin, Min He, Yi-Yu Chen, Yun-Song Yang, Hu-Yun-Long Zhang, Lei Fan, Jiong Wu, Rong-Hua Liu, Yi-Zhou Jiang, Zhi-Ming Shao
Zitieren
APA
Fu, T., Jin, X., He, M., Chen, Y. Y., Yang, Y. S., Chen, L., Zhang, H. Y., Fan, L., Wu, J., Wang, Z. H., Chu, Y. W., Liu, R. H., Jiang, Y. Z., & Shao, Z. M. (2025). Interferon-induced senescent CD8 + T cells reduce anti-PD1 immunotherapy efficacy in early triple-negative breast cancer. Science Translational Medicine, 17(815). https://doi.org/10.1126/scitranslmed.adj7808
Vancouver
Fu T, Jin X, He M, Chen YY, Yang YS, Chen L, et al. Interferon-induced senescent CD8 + T cells reduce anti-PD1 immunotherapy efficacy in early triple-negative breast cancer. Science Translational Medicine. 2025;17(815). doi:10.1126/scitranslmed.adj7808
BibTeX
@article{Fu2025,
author = {Fu, Tong and Jin, Xi and He, Min and Chen, Yi-Yu and Yang, Yun-Song and Chen, Li and Zhang, Hu-Yun-Long and Fan, Lei and Wu, Jiong and Wang, Zhong-Hua and Chu, Yi-Wei and Liu, Rong-Hua and Jiang, Yi-Zhou and Shao, Zhi-Ming},
title = {Interferon-induced senescent CD8 + T cells reduce anti-PD1 immunotherapy efficacy in early triple-negative breast cancer},
journal = {Science Translational Medicine},
year = {2025},
volume = {17},
number = {815},
doi = {10.1126/scitranslmed.adj7808}
}
EUVIMED